Abbasi Anwar Hussain, Abid Shahab, Haq Tanveer Ul, Awan Safia
Aga khan University Hospital, Karachi, Pakistan.
J Ayub Med Coll Abbottabad. 2017 Jul-Sep;29(3):378-383.
The objective behind this study was to determine that Assessment for Retreatment with Transarterial chemoembolization (ART) score is really applicable in patients with hepatocellular carcinoma.
A cross sectional observational study was conducted on all patients with hepatocellular carcinoma of intermediate stage and undergone ≥2 Transarterial chemoembolization. ART score was assessed before and after each session of Transarterial chemoembolization. Multi-logistic regression analysis was performed to compare the final outcome of patients with ART score of ≥2.5 into groups with two and more than two Trans-arterial chemo-embolization sessions.
A total of 100 HCC patients were recruited for final analysis. Our study participants consisted of total 100 HCC patients. Mean Child Pugh score was 6.1±0.95. In our study, most of the study participants (n=63) had ART score of less than 1.5 as compared to ART score >2.5 (n=37). A significant proportion of patients with ART score of <1.5 prior to second Trans-arterial chemo-embolization had better median survival as compared to patients with ART score of >2.5, p-value<0.001. Patients with ART score of more than 2.5 did not show any survival benefit after having 3rd or 4th Trans-arterial chemo-embolization session, p=0.47.
Our study findings suggest that those HCC patients who receive multiple sessions of TACE with a low ART score have more favourable outcomes with increased survival rate.
本研究的目的是确定经动脉化疗栓塞(ART)再治疗评估评分在肝细胞癌患者中是否真的适用。
对所有中期肝细胞癌且接受过≥2次经动脉化疗栓塞的患者进行横断面观察研究。在每次经动脉化疗栓塞前后评估ART评分。进行多因素逻辑回归分析,以比较ART评分≥2.5的患者在接受两次及两次以上经动脉化疗栓塞治疗后的最终结局。
共招募了100例肝癌患者进行最终分析。我们的研究参与者共有100例肝癌患者。Child-Pugh平均评分为6.1±0.95。在我们的研究中,与ART评分>2.5(n=37)的患者相比,大多数研究参与者(n=63)的ART评分低于1.5。与ART评分>2.5的患者相比,第二次经动脉化疗栓塞前ART评分<1.5的患者中位生存期显著更长,p值<0.001。ART评分超过2.5的患者在接受第3次或第4次经动脉化疗栓塞后未显示出任何生存获益,p=0.47。
我们的研究结果表明,那些接受多次TACE且ART评分较低的肝癌患者有更有利的结局,生存率更高。